Exelixis Inc Contract with Customer, Asset, Reclassified to Receivable
Exelixis Inc (EXEL) reported Contract with Customer, Asset, Reclassified to Receivable of $947.00 thousand for the 6-month period ending 2019-06-28, per its 10-Q filed 2019-07-31.
Discontinued › Notes › Revenue from Contract with Customer › Change in Contract with Customer, Asset and Liability
us-gaap:ContractWithCustomerAssetReclassifiedToReceivable · last filed 2019-07-31
- Exelixis Inc contract with customer, asset, reclassified to receivable for the quarter ending 2019-06-28 was $404.00K.
- Exelixis Inc contract with customer, asset, reclassified to receivable for the quarter ending 2019-03-29 was $543.00K, a 94.07% decline year-over-year.
- Exelixis Inc contract with customer, asset, reclassified to receivable for the quarter ending 2018-12-28 was $36.94M.
- Exelixis Inc contract with customer, asset, reclassified to receivable for the quarter ending 2018-09-28 was $0.00.
- Exelixis Inc contract with customer, asset, reclassified to receivable for fiscal 2018 was $46.05M.
| Period end | Contract with Customer, Asset, Reclassified to Receivable 3 month | Contract with Customer, Asset, Reclassified to Receivable 6 month | Contract with Customer, Asset, Reclassified to Receivable 9 month | Contract with Customer, Asset, Reclassified to Receivable 12 month |
|---|---|---|---|---|
| 2019-06-28 | $404.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | $947.00K 10-Q · filed 2019-07-31 | $37.89M derived: sum of 3 quarters · filed 2019-07-31 | $37.89M derived: sum of 4 quarters · filed 2019-07-31 |
| 2019-03-29 | $543.00K 10-Q · filed 2019-05-01 | $37.49M derived: sum of 2 quarters · filed 2019-05-01 | $37.49M derived: sum of 3 quarters · filed 2019-05-01 | $37.44M derived: sum of 4 quarters · filed 2019-05-01 |
| 2018-12-28 | $36.94M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | $36.94M derived: sum of 2 quarters · filed 2019-02-22 | $36.89M derived: sum of 3 quarters · filed 2019-02-22 | $46.05M 10-K · filed 2019-02-22 |
| 2018-09-28 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | -$50.00K derived: sum of 2 quarters · filed 2018-11-01 | $9.11M 10-Q · filed 2018-11-01 | |
| 2018-06-29 | -$50.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-01 | $9.11M 10-Q · filed 2018-08-01 | ||
| 2018-03-30 | $9.16M 10-Q · filed 2018-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |